Search
Nusinersen
go.drugbank.com/drugs/DB13161ApprovedInvestigationalAn antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S. … FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.
Dalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.
Categories: OCT2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic IndexEthosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Dequalinium
go.drugbank.com/drugs/DB04209Approved[A249255] It is a quaternary ammonium compound,[L42190] as it consists of an amphipathic cation with two aminoquinaldinium rings at both ends of a long hydrophobic hydrocarbon chain. … [A249255] First used as an antiseptic and disinfectant in the 1950s, dequalinium is still found in various OTC products to treat conditions of oral infections and inflammation.
Levothyroxine
go.drugbank.com/drugs/DB00451ApprovedInvestigational[F4633] T<sub>4</sub> and T<sub>3</sub> act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. … [F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T<sub>4</sub>, which is then converted through
Mixtures: L THYROX JOD HEXAL 50/150, L THYROX JOD HEXAL 50/150Categories: UGT1A1 Substrates with a Narrow Therapeutic IndexSertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt is a phenylindole derivative used in the treatment of schizophrenia. … It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects.
Bremelanotide
go.drugbank.com/drugs/DB11653Approved[A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown. … Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women.[L9635] Bremelanotide does not interact with alcohol.
Hydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus … [L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect.
Products: AA PHARMA HYDROXYZINE CAPSULE 10 mg, AA PHARMA HYDROXYZINE CAPSULE 25 mgTyloxapol
go.drugbank.com/drugs/DB06439ApprovedInvestigationalTyloxapol is a non-ionic detergent often used as a surfactant.
Categories: Compounds used in a research, industrial, or household settingMycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigationalMycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. … Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A6 Substrates with a Narrow Therapeutic IndexSynonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid